HBeAg positivity in patients of HBV/CD1 or HBV/C2.

<p>Patients were stratified by age into three groups, younger than 30 years (<30), 30–50 years and older than 50 years (>50). The prevalence of HBeAg decreased with age in patients of HBV/C2 (58.8% in <30 years; 48.0% in 30–50 years; 33.3% in >50 years), whereas almost no change was observed in patients of HBV/CD1 (21 of 32, 65.6% in <30 years; 39 of 63, 61.9% in 30–50 years; 9 of 14, 64.3% in >50 years). The rate of HBeAg positivity did not reach the statistical significance in all three age groups between HBV/CD1 and HBV/C2 (<i>P</i> = 0.758, 0.244 and 0.336 in <30, 30–50 and >50 years respectively).</p

Distribution of HBV genotypes by geographical region and ethnicity in western China.

<p>*Data are given as age range (means ± standard deviations).</p

Phylogenetic analysis of mosaic sequences of the HBV C/D recombinant compared with reference strains representing genotypes A–G.

<p>Accession numbers and sample numbers are shown on each branch, and are indicated on the left by the HBV genotype or subgenotype. Bootstrap values are shown along each main branch. Scale bars indicate the nucleotide divergence. Isolates determined in this study are marked. A, Phylogenetic tree based on nt 10-799. B, Phylogenetic tree based on nt 10-1499.</p

Clinical and virological differences of HBV/CD1 and HBV/C2.

<p><b>NOTE.</b> Data are given as mean±SD or no. (%) of patients. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin.</p

Distribution of HBV genotype by geographical location in western China.

<p>The proportion of the HBV C/D recombinants (‘CD1’ and ‘CD2’) in each region is shown. The complete names of regions mentioned in this figure are as follows: XJ = Xinjiang, QH = Qinghai, GS = Gansu, NX = Ningxia.</p

Supplementary – Supplemental material for Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis

<p>Supplemental material, Supplementary for Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis by Dongjing Zhang, Zhihong Liu, Xueru Yin, Xiaolong Qi, Bingyun Lu, Yuanyuan Liu and Jinlin Hou in The International Journal of Biological Markers</p

Additional file 1: Figure S1. of High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs

HF and HFC diets lead to hepatic steatosis in zebrafish larvae. Figure S2. Lipid accumulation in the livers and blood vessels of zebrafish larvae fed with HF and HFC diets. Figure S3. Genes changes in the livers of HF and HFC diets-fed zebrafish larvae. Table S1. Primer sequences used for quantitative RT-PCR. (DOCX 2678 kb

Flow of participants in the study and family trees of family with mixed genotypes/subgenotypes HBV infection.

<p>Circles and rectangles correspond to female and male individuals, respectively. Family name and birth date of the patients are indicated beside the circles and rectangles. Subgenotype and the year of blood sampling are indicated inside the circles and rectangles. Family V with affected members across two generations and two genotypes/subgenotypes. Family Q with affected members across three generations and two genotypes/subgenotypes. Family Y with affected members across three generations and three genotypes/subgenotypes. Specially, father (Y2) of family Y with triplicate infection of genotype C, D and CD recombinant in 2006. N.T: Not tested for HBV DNA level below the detection limit of the nested PCR assay or no serum was available.</p

Necroinflammation grade and fibrosis stage in HBeAg-positive patients.

<p>(A) Necroinflammation grade in HBeAg-positive patients. Significant necroinflammation (≥A2) was found 1.2%, 23.8% and 51.1% in PNALT, ALT 1-2×ULN and >2×ULN group, respectively. (B) Fibrosis stage in HBeAg-positive patients. Significant fibrosis (≥F2) was found 49.4%, 69.8% and 81.6% in PNALT, ALT 1-2×ULN and >2×ULN group, respectively. Significant histological abnormalities in >2×ULN group were much higher than those in PNALT or ALT 1-2×ULN group (both P < 0.001).</p

Flow chart describing the selection of the study population.

<p>459 subjects were finally recruited for analysis.</p